"Delivering Oligonucleotides as Phosphotriesters"


Scott Petersen, Ph.D.

The President  and CEO


Eric Nilson 

Chief Technology Officer, Board Member & Corporate Secretary​

Eric Nilson is a Partner at QED Dynamics Inc., a Southern California-based consulting firm which specializes in leveraging informatics for biopharmaceutical and molecular diagnostic companies. After serving in the United States Marine Corps, Mr. Nilson has focused on establishing expertise in the areas of technology development, information security, operations, and commercialization in the Life Sciences domain.  Before joining Triphos Therapeutics, Inc., Mr. Nilson worked on developing and bringing to market numerous new products – some with annual revenue projections in excess of $1B.  

Curt Becker

As a founder of Applied Biosystems Inc., Curt Becker was in the forefront of developing, commercializing and supporting many of the enabling technologies of the biotech industry including automated DNA synthesis, DNA sequencing and QPCR.  As ABI grew to the Fortune 1000, Mr. Becker grew along with it and took part in many aspects of the business including product development, product management, sales and sales management and European marketing management.In 2006, Mr. Becker founded New Dimension Performance; a strategic development, planning and implementation partner for technology development business executives and their teams.

Currently, Mr. Becker is a co-founder, CEO and president of Molecular Assemblies which is developing a next generation DNA synthesis technology.Mr. Becker participates in the community by contributing as a marketing domain expert with Connect’s Springboard program and volunteers his time to support various STEM educational programs.


NIcolas Dean,Ph.D

Dr. Nicolas M. Dean joined the TriPhos Therapeutics Scientific Advisory Board in March of 2013.   Dr. Dean is an accomplished and prolific leader in the field of oligonucleotide therapeutics, he has been listed on over 100 patents, he authored 38 issued patents  and has written more than

120 papers in the fields of genomics, antisense and oligonucleotide technology, and oncology.  

As a thought leader in the industry he participated in the editorial board of Antisense & Nucleic Acid Research and Drug Discovery Today: Technologies. Dr. Dean received his Bachelor of Science degree from the University of Wales, and his doctorate in Pharmacology from the Welsh National School of Medicine.  

Dr. Dean founded Excaliard Pharmaceuticals in 2006 –  a biotechnology  company focused on developing antisense-based drugs to treat fibrosis and skin scarring. He served as a Director of Excaliard Pharmaceuticals, Inc. until their successful acquisition by  Pfizer in 2011.   Prior to Excaliard, Dr. Dean was Vice President of Functional Genomics and Oncology at Isis Pharmaceuticals, where he also served as Managing Director of Isis Singapore and various other roles during his highly productive 15 year tenure. 

 Dr. Dean has served as member of the Scientific Advisory Board of RXi Pharmaceuticals Corp and Arcturus Therapeutics. 

“Nick is a tremendous asset for the company, he brings both high level business and field specific scientific experience to TriPhos Therapeutics Inc.  His entrepreneurial nature and vision will help guide all stages of corporate growth where he will provide outstanding value for our partners and shareholders.   We are very fortunate to have him aboard”. said Scott G. Petersen, President and CEO, TriPhos.  


Gerald Yakatan, Ph.D

Gerald J. Yakatan, Ph.D. is a serial entrepreneur who has been a founder of multiple companies in the pharmaceutical R&D arena and currently serves as Chairman & CEO of IriSys, Inc., a CDMO specializing in formulation development and GMP manufacturing of clinical trials materials and commercial products. He is also Chairman & CEO of  MeiHua Biopharma. 

He served as President & CEO of Avanir Pharmaceuticals where he led development efforts resulting in the NDA submission for Nuedexta® and was responsible for the development, regulatory approval and commercialization of Abreva®.  Dr. Yakatan has also served as Pharmaceutics Chair at University of Texas at Austin; VP for Product Development Worldwide at Warner Lambert/Parke Davis; and  Founder and CEO at Tanabe Research Labs, USA.  He has served on the Boards of numerous not-for-profit organizations and received distinguished alumnus awards from Temple University and from the University of Florida. His MeiHua Biopharma company in China is focused on accelerating discovery and development of novel anti-inflammatory therapeutics.​